APLIKASI KO-KEMOTERAPI FRAKSI ETIL ASETAT EKSTRAK ETANOLIK DAUN SAMBUNG NYAWA (GYNURA PROCUMBENS (LOUR.) MERR.) PADA SEL KANKER PAYUDARA MCF-7
| Main Authors: | Jenie, Riris Istighfari; Fakultas Farmasi, UGM, Sekip Utara Yogyakarta 55281, Meiyanto, Edy; Fakultas Farmasi, UGM, Sekip Utara Yogyakarta 55281 |
|---|---|
| Format: | Article info application/pdf eJournal |
| Bahasa: | eng |
| Terbitan: |
Directorate of Research and Community Engagement, Universitas Indonesia
, 2012
|
| Online Access: |
http://psr.ui.ac.id/index.php/journal/article/view/3442 http://psr.ui.ac.id/index.php/journal/article/view/3442/520 |
Daftar Isi:
- Combination chemotherapy has been an interesting attention in recent years to cure cancer e.g. non-toxic or less toxic phytochemicals are being combined with chemo-therapeutic agents to sensitize cancer cell and to enhance the efficacy of chemothera-peutic agents as well as to reduce its toxicity to normal tissues. The aim of this research is to examine whether ethyl acetate fraction of Gynura procumbens ethanolicextract (SEF) synergizes the therapeutic potential of doxorubicin (Dox) on breast cancer cell line MCF-7. MTT assay were used to measure the growth inhibitory effect of the combination therapy on MCF-7 cells. SEF (5-250 µg/ml) treatment of cellresulted in 15-76% growth inhibition in a dose dependent manner (IC50 85 µg/ml), while Dox (10-100 nM) treatment did not show any inhibitory effect. The combina-tions of SEF (5-40µg/ml) with Dox (10-75 nM) seemed to not have any synergistic efficacy towards cell growth inhibition. Nevertheless, this result need further observa-tion regarding the IC50 of Dox on MCF-7 has not been determined yet. The cellcharacterization may influence the result. Doxorubicin could induce Akt survival apoptosis pathway in MCF-7 resulting resistancy of the cell towards doxorubicin.Key words: MCF-7 human mammary cancer cell, Doxorubicin, Sambung Nyawaleaves ethanolic extract, co-chemotherapy.